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Abstract
Background: The World Health Organization (WHO) has set goals for onchocerciasis elimination in Latin America
by 2015. Most of the six previously endemic countries are attaining this goal by implementing twice a year (and in
some foci, quarterly) mass ivermectin (Mectizan®) distribution. Elimination of transmission has been verified in
Colombia, Ecuador and Mexico. Challenges remain in the Amazonian focus straddling Venezuela and Brazil, where
the disease affects the hard-to-reach Yanomami indigenous population. We provide evidence of suppression of
Onchocerca volvulus transmission by Simulium guianense s.l. in 16 previously hyperendemic Yanomami communities
in southern Venezuela after 15 years of 6-monthly and 5 years of 3-monthly mass ivermectin treatment.
Methods: Baseline and monitoring and evaluation parasitological, ophthalmological, entomological and serological
surveys were conducted in selected sentinel and extra-sentinel communities of the focus throughout the
implementation of the programme.
Results: From 2010 to 2012–2015, clinico-parasitological surveys indicate a substantial decrease in skin microfilarial
prevalence and intensity of infection; accompanied by no evidence (or very low prevalence and intensity) of ocular
microfilariae in the examined population. Of a total of 51,341 S. guianense flies tested by PCR none had L3 infection
(heads only). Prevalence of infective flies and seasonal transmission potentials in 2012–2013 were, respectively,
under 1 % and 20 L3/person/transmission season. Serology in children aged 1–10 years demonstrated that
although 26 out of 396 (7 %) individuals still had Ov-16 antibodies, only 4/218 (2 %) seropositives were aged 1–5
years.
Conclusions: We report evidence of recent transmission and morbidity suppression in some communities of the
focus representing 75 % of the Yanomami population and 70 % of all known communities. We conclude that
onchocerciasis transmission could be feasibly interrupted in the Venezuelan Amazonian focus.
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Background
Onchocerciasis is a chronic and cumulative skin and
ocular disease caused by infection with the filarial nema-
tode Onchocerca volvulus Leuckart and transmitted
among humans through the bites of blackfly species of
the genus Simulium Latreille. The embryonic stages of
the parasite (microfilariae, mf) migrate through the skin
and cause severe itching, skin disease, and ocular lesions,
with the severity of the clinical manifestations depending
on the length of exposure to blackfly bites and the dens-
ity of mf in the skin [1, 2]. Visual loss and blindness can
result from exposure to heavy parasite loads in the hu-
man host over time [2]. Since blackflies breed in fast
flowing rivers, the disease is also known as ‘river blind-
ness’, although in the Americas it is called Robles’ Dis-
ease after Rodolfo Robles, who described it one hundred
years ago in Guatemala [3].
In the Americas, the infection was formerly prevalent
in 13 endemic foci distributed in 6 countries (Brazil,
Colombia, Ecuador, Guatemala, Mexico and Venezuela),
where 565,232 persons were considered at risk of infec-
tion [4]. In Venezuela, there were three onchocerciasis
foci (north-eastern, north-central, and southern), of
which, the latter remains as the only persistent focus of
the infection in the country [4, 5]. The southern focus
comprises endemic areas in the rainforest of the Upper
Orinoco, Upper Siapa and Upper Caura River basins (in
the Venezuelan Guayana), affecting the Yanomami indi-
genous group and extending beyond the border with
Brazil to join the Yanomami Brazilian area to form the
onchocerciasis Amazonian focus [6]. This is the largest
focus by area in Latin America, affecting 26,715 people
[4], of which 13,231 (49.5 %) are in the Venezuelan part
of the focus. The southern focus shows an epidemio-
logical spatial gradient, including areas of high transmis-
sion intensity with substantial levels of cutaneous and
ocular morbidity observed prior to the start of the elim-
ination programme. In the hyperendemic communities
of the focus, skin disease was highly prevalent, with
24 % of the population affected by lichenified onchoder-
matitis and 10 % suffering from skin atrophy [7]. The
pre-treatment prevalence of onchocercal nodules (onch-
ocercomata), especially on the head, was 29 %, reaching
51 % in some communities (e.g., in Orinoquito). Pres-
ence of lymphatic lesions―including hanging groin―-
previously described in Africa was also reported [8].
Similarly, ocular pathology—up to 50 % prevalence of
punctate keratitis, mainly due to the presence of mf in
the cornea (MFC) and up to 75 % prevalence of mf in
the anterior chamber of the eye (MFAC)—was a major
clinical manifestation attributable to onchocerciasis. In
some hyperendemic communities of the Parima area,
the prevalence of any onchocerciasis-associated ocular
lesions was greater than 50 %, reaching up to 70 % in
those individuals aged ≥40 years. The prevalence of irre-
versible ocular lesions such as sclerosing keratitis (cu-
mulative inflammatory lesions in the cornea that do not
regress but cause progression to eye damage and irre-
coverable loss of vision) reached up to 17 % in the Ori-
noquito area. Bilateral blindness due to onchocerciasis
was observed in 0.45 % of the general population [8].
Simulium guianense sensu lato (s.l.) Wise, S. incrusta-
tum Lutz, and S. oyapockense s.l. Floch and Abonnenc
are the main vectors in the Southern Focus of
Venezuela, with the former species being the most com-
petent for O. volvulus and the predominant human-
biting blackfly in most of the hyperendemic areas of the
focus [9, 10]. Simulium incrustatum, with a lower vector
competence than S. guianense s.l., contributes to the
transmission of onchocerciasis in mesoendemic and
some hyperendemic areas, whereas S. oyapockense is the
main vector in hypoendemic communities with low in-
tensity of transmission [10–12].
The strategy adopted by the Onchocerciasis Elimin-
ation Program for the Americas (OEPA) since its com-
mencement in 1993 has included elimination of new
(ocular) morbidity caused by O. volvulus, and interrup-
tion of transmission by 6-monthly mass administration
of ivermectin (Mectizan®, donated by Merck & Co Inc),
delivered by mobile teams with a therapeutic coverage
≥85 % of eligible population in all the endemic commu-
nities of the region, including hypoendemic areas [13,
14]. (Given that, on average, approximately 15 % of the
population are commonly not eligible for ivermectin
treatment, this translates into a therapeutic coverage
≥70 % of the total population.) Ivermectin kills the mf
and temporarily inhibits their release by gravid adult fe-
male worms [15], as well as killing adult worms after
several years of mass treatment given at 6-monthly inter-
vals [16, 17]. More recently, 3-monthly treatments have
been introduced in some communities in Mexico and
Venezuela [6, 18], given the results of clinical trials con-
ducted in Guatemala [19] and Africa [20]. The OEPA
strategy has led to the elimination of incident cases of
ocular disease and the interruption of transmission in 11
of the formerly 13 endemic foci [4]; the two remaining
foci being the Venezuelan and the Brazilian parts of the
Amazonian focus.
The present work reports on the progress towards on-
chocerciasis elimination in southern Venezuela, accord-
ing to the protocols proposed by the World Health
Organization (WHO), which include in-depth parasito-
logical, entomological and serological surveys, as well as
guidance on operational thresholds [21]. Specifically, we
report evidence of recent suppression (as defined in
[21]) of O. volvulus transmission by S. guianense s.l. in
16 sentinel and extra-sentinel (previously hyperendemic)
communities localized in different geographical areas of
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the southern Venezuelan focus after 15 years of 6-
monthly and 5 years of 3-monthly mass drug adminis-
tration (MDA) of ivermectin.
Methods
Ethics approval and consent to participate
The parasitological, clinical, entomological and sero-
logical studies received ethical clearance from the Ethics
Review Committee of CAICET (as part of the Ministerio
del Poder Popular para la Salud–Venezuelan Ministry of
Health). All the participants signed an informed consent
form before undergoing any examination, testing, or
agreeing to help as human attractants for entomological
collections. Additionally, there was active participation
of Yanomami volunteers (and their organization “Horo-
nami”) in the identification of new communities and dis-
tribution of ivermectin across the focus.
Study area and study population
Onchocerciasis transmission in southern Venezuela oc-
curs in the lowlands (0–500 m above sea level, asl) and
uplands (500–1200 m asl) of the Upper Orinoco, Upper
Siapa and Upper Caura River basins (in the Amazonas
and Bolivar States), which are part of the ancient
Guayana Shield of northern South America, the oldest
(3600 million years) region of the world (Fig. 1).
Additional file 1 describes in detail the geographical and
environmental characteristics of the focus pertinent to
the transmission of onchocerciasis (see Text S1. Geo-
graphical and environmental characteristics of the Vene-
zuelan part of the Amazonian onchocerciasis focus). The
main onchocerciasis transmission seasons (regardless of
the Simulium vector species present), occur during the
dry to rainy (February–April) and rainy to dry (Septem-
ber–November) transitions [11]. The Yanomami indi-
genous group is the human population afflicted by
Fig. 1 Venezuelan part of the Amazonian onchocerciasis focus. The legend lists the 12 geographical areas of the focus coloured by baseline
endemicity of Onchocerca volvulus infection, from lowest (light blue) in Ventuari to highest (dark red) in Orinoquito. The numbers indicate the 31
geographical sub-areas described in Table 1
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onchocerciasis in the Amazonian focus, with more than
25,000 inhabitants and four distinct linguistic subgroups
(Yanomami, Yanomam, Yanam, and Sanemá), of which
the Yanomami is the most affected in Venezuela (Amazo-
nas State), followed by the Sanemá (Bolivar State).
The Venezuelan part of the focus encompasses 12 geo-
graphical areas: Padamo; Ocamo; Mavaca; Platanal;
Guaharibos; Orinoquito; Parima; Chalbaud; Ventuari;
Uasadi; Caura, and Siapa. Within these 12 main areas,
31 geographical sub-areas have been described (Fig. 1
and Table 1). Further details of the endemic communi-
ties, mapping and geographical information system can
be found in Additional file 1 (see Text S2. Endemic com-
munities, mapping and geographical information system).
The (mostly semi-nomadic) Yanomami at-risk popula-
tion has been estimated as 13,231 people, living in 241
‘shaponos’ scattered deep in the forest, and practicing
shifting cultivation, hunting, fishing and gathering of for-
est products [6]. Their scanty clothing leads to an almost
continuous exposure to biting blackflies. Further details
Table 1 Onchocerciasis endemic communities by geographical area and sub-area, population at risk and population eligible for
ivermectin treatment in the Amazonian focus of southern Venezuela
Geographical
area
Geographical sub-areaa No of communities per endemicity levelb Population
at risk
Eligible
population (%)Hyperendemic Mesoendemic Hypoendemic
Padamo 1. Upper Padamo 0 0 6 617 529 (85.7)
2. Upper Cuntinamo 0 3 1 225 188 (83.6)
Ocamo 3. Ocamo–Orinoco 0 0 4 245 223 (91.0)
4. Lower Ocamo 0 2 5 279 249 (89.3)
5. Middle Ocamo 0 5 1 508 481 (94.7)
6. Jénita–Putaco 4 0 0 218 192 (88.1)
7. Upper Ocamo–Shitari 17 2 1 755 660 (87.4)
8. Upper Ocamo–Parima 16 4 0 589 497 (84.4)
Mavaca 9. Mavaca–Orinoco 0 0 12 927 804 (86.7)
10. Manaviche 0 1 1 140 129 (92.1)
11. Mavaca 0 0 3 216 193 (89.4)
12. Mavaquita 0 0 11 944 841 (89.1)
Platanal 13. Platanal 3 70 10 569 506 (88.9)
Guaharibos 14. Unturán 5 0 0 338 307 (90.8)
15. Guaharibos 2 0 0 139 123 (88.5)
16. Peñascal 3 0 0 255 216 (84.7)
Orinoquito 17. Mayo 8 0 0 477 407 (85.3)
18. Orinoquito 14 0 0 795 688 (86.5)
Parima 19. Parima B 25 0 0 1045 843 (80.7)
20. Parima C 9 0 0 609 505 (82.9)
21. Parima A 19 0 0 917 789 (86.0)
22. Porewë 7 0 0 247 218 (88.3)
23. Pasumopë 5 0 0 296 260 (87.8)
24. Shamatari 4 0 0 289 250 (86.5)
25. Posheno 3 0 0 146 121 (82.9)
Chalbaud 26. Hashimú 7 0 0 356 321 (90.2)
27. Chalbaud 10 0 0 300 258 (86.0)
Ventuari 28. Upper Ventuari 0 0 1 136 118 (86.8)
Uasadi 29. Uasadi 0 0 2 176 148 (84.1)
Caura 30. Upper Caura 0 1 0 72 68 (94.4)
Siapa 31. Upper Siapa 6 0 0 406 324 (79.8)
Total (%) 167 (69.3) 25 (10.4) 49 (20.3) 13,231 11,456 (86.6)
a The numbering of the geographical sub-areas corresponds to that indicated in the map of Fig. 1
b Endemicity levels defined as: hyperendemic, microfilarial prevalence ≥60 %; mesoendemic, mf prevalence = 20–59 %; hypoendemic, mf prevalence <20 % [24]
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on how the anthropological features of the Yanomami
influence their exposure to onchocerciasis have been
presented elsewhere [6, 22, 23].
Baseline endemicity and survey communities for
monitoring and evaluation
According to OEPA guidelines [24], those communities
with a microfilarial prevalence lower than 20 % are clas-
sified as hypoendemic; those with prevalence between 20
and 59 % as mesoendemic, and those communities with
a prevalence of 60 % or greater as hyperendemic. Table 1
presents the number of communities thus classified and
the population at risk and eligible for ivermectin treat-
ment in the 12 geographical areas and 31 geographical
sub-areas of the Venezuelan part of the Amazonian
focus. The population at risk, 13,231 people as of 2015,
was calculated based upon regularly updated demo-
graphic censuses conducted by the mobile teams that
distribute ivermectin treatment. The population eligible
for mass administration of ivermectin, 11,456 (86.6 %)
people, were those aged five years or older, excluding
those weighing less than 15 Kg (or measuring less than
90 cm in height), pregnant women and those breastfeed-
ing a child younger than one week old (representing
13.4 % of the population).
The pre-treatment levels of endemicity across all geo-
graphical areas were very heterogeneous (Table 1), with
some areas including communities that were all hyper-
endemic (e.g., Orinoquito, Parima, Chalbaud), and
others where hypoendemic communities prevailed (e.g.,
Padamo, Mavaca) [25]. In other areas (Ocamo), a grad-
ual increase with increasing altitude in the proportion of
hyperendemic communities has been observed [6, 7, 22],
with hypoendemic communities in the low reaches of
the Ocamo river (Lower Ocamo, 5 communities),
mesoendemic communities in the middle reaches of the
Ocamo river (Middle Ocamo, 5 communities) and hy-
perendemic communities in the upper reaches of the
Ocamo river (Upper Ocamo–Shitari, 17 communities
and Upper Ocamo–Parima, 16 communities), as sum-
marized in Table 1. Overall, of the 241 endemic commu-
nities, 167 (69.3 %) were hyperendemic and mostly
localized in the Ocamo, Siapa, Guaharibos, Chalbaud,
Parima, and Orinoquito areas (Fig. 1), where the pre-
dominant anthropophagic blackfly species is S. guianense
s.l. in most of the localities [6, 22].
The criteria for selection of sentinel and extra-sentinel
communities for regular monitoring and evaluation ac-
tivities, consisting of in-depth epidemiological evalua-
tions included: a) hyperendemic status, b) relative ease
of accessibility by the mobile teams that conduct such
evaluations, c) existence of historical, baseline epidemio-
logical data prior to wide-spread ivermectin distribution;
d) illustrative of the simuliid species composition of the
focus. Accordingly, eight communities were selected as
sentinel communities, namely (omitting the suffix ‘theri’
that designates the place name for a Yanomami village,
for simplicity): (1) Hasupiwei (altitude: 200 m asl; 73 in-
habitants) in Guaharibos–Unturán; (2) Awei (162 m asl;
30 inhabitants) and (3) Pashopëka (240 m asl; 89 inhabi-
tants) in Upper Ocamo–Shitari; (4) Koyowë (= Coyowë)
(250 m asl; 129 inhabitants), (5) Waharafitha—previously
Fubalema—(260 m asl; 97 inhabitants) and (6) Matoa
(360 m asl; 48 inhabitants) in Orinoquito; and (7)
Kanoshewë (819 m asl; 66 inhabitants) and (8) Niayo-
pë—previously Niyayowë—(950 m asl; 86 inhabitants) in
Parima–Shamatari. Since the size of Yanomami communi-
ties is generally small, to increase sample size an
additional 8 villages were selected as extra-sentinel com-
munities. These were: (9) Yaurawë (198 m asl; 115 inhabi-
tants) in Guaharibos–Unturán; (10) Masiriki (990 m; 44
inhabitants) and (11) Toumawei (1037 m asl; 32 inhabi-
tants) in Parima (A); (12) Arokofita (871 m asl; 67 inhabi-
tants) and (13) Okiamo (927 m asl; 58 inhabitants) in
Parima (B); (14) Warapawë (1007 m asl; 110 inhabitants)
in Parima (C); and (15) Kakarama (669 m asl; 57 inhabi-
tants) and (16) Pokoshiprare (721 m asl; 90 inhabitants) in
the Parima–Shamatari sub-area within the Parima area,
the latter two communities derived from Yoreshiana A
and Yoreshiana B (see [26]).
History of mass ivermectin treatment in the Amazonian
focus
In the Amazonian focus, annual ivermectin distribution
commenced in 1993 only in a few communities, and
with a low mean therapeutic coverage (of less than 60 %
up to 2000; Fig. 2a). This period is henceforth referred
to as ‘pre-ivermectin MDA’, given the low geographical
and therapeutic coverage that had been achieved. From
2000 onwards (period henceforth referred to as ‘during
ivermectin MDA’), the onchocerciasis elimination
programme in Venezuela was drastically re-organised
under OEPA’s strategic plan and started 6-monthly iver-
mectin treatment, with steadily increasing coverage. The
85 % coverage goal (for each treatment round) was
reached in 2006 throughout the focus and it has been
sustained since then (Fig. 2a). Treatment frequency was
further increased from twice to four times per year in 45
communities during 2009 and currently, this quarterly
treatment regimen has been extended to 192 out of 241
(80 %) of the endemic communities in the focus, albeit
with a slight decreasing trend in coverage for the second
to the fourth quarterly rounds (Fig. 2b). This treatment
approach was adopted to accelerate interruption of
transmission and to accelerate the death of adult worms,
especially in areas with very high vector biting density,
in communities whose mf prevalence and intensity
seemed to have reached a new (lower than baseline)
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pseudo-equilibrium, or in communities that had been
recently identified and incorporated into the programme
at later stages. The number of treatment rounds per geo-
graphical sub-area that attained a coverage ≥85 % during
1995–2015 was calculated dividing the total number of
treatments per sub-area in each round by the eligible
population for this period (Fig. 3). Although the quar-
terly treatment regimen is more difficult to sustain at a
consistently high 85 % coverage for each round, particu-
larly for the most remote communities and during some
times of the year, the greater frequency of visits to each
community has meant that at least two complete treat-
ment rounds with a coverage ≥85 % are received annu-
ally by each at-risk community. Table S1 of Additional
file 1 provides details, for the 31 geographical sub-areas
of the focus, of the number of twice-yearly and quarterly
ivermectin rounds achieving ≥85 % therapeutic coverage.
(The criteria for transmission suppression as reported in
this article are described in Additional file 1: Text S3.
World Health Organization (WHO) criteria for oncho-
cerciasis elimination.)
Parasitological and ophthalmological surveys
Parasitological surveys were carried out in the sentinel
and extra-sentinel communities of the focus at baseline
(1981), pre-ivermectin MDA (1995–1998, 2000, the lat-
ter just before the twice per year treatment), and during
ivermectin (twice a year and subsequently quarterly)
MDA (2001, 2008, 2013, 2015). The skin snip method
was used to determine the prevalence and intensity of O.
volvulus mf. Two skin biopsies from the (right and left)
iliac crests were taken from each examined individual
with a 2-mm Holth corneoscleral punch, and incubated
for 24 h in buffered saline solution; the emerging mf
were counted under an inverted microscope and snips
were weighed to express results as mf/mg [8, 26]. When
it was not possible to weigh the snips in the field, an
average weight of 1.62 mg was used, based on data col-
lected in [22, 26].
Ophthalmological evaluations were carried out during
similar periods (1981 for baseline; 1997–1998 and 2000
for pre-ivermectin MDA, and 2001, 2008, 2015, during
ivermectin MDA). The prevalence of microfilariae in
cornea (MFC) and/or in the anterior chamber (MFAC)
was determined by an ophthalmologist experienced in
conducting onchocerciasis ocular evaluations for OEPA
(HM). Ocular examinations were conducted with a slit-
lamp in a darkened area after patients were asked to sit
with their head between their legs for 5 min to allow any
mf present in the anterior chamber to settle in a visible
position in order to determine MFAC [24, 27]. The cri-
terion of [27] was followed of taking into account only
non-inflammatory keratitis lesions, with evidence of the
presence of live or dead mf in the cornea (punctate kera-
titis stages A and B), as an indicator of MFC. (According
to [27], inflammatory punctate keratitis (stages C, D, and
E) is neither specific nor a reliable indicator of
onchocerciasis-associated ocular disease.) Baseline and
pre-ivermectin MDA data were obtained on i) skin mf
prevalence and ii) skin mf intensity as both arithmetic
(AM) and Williams (WM) mean numbers of mf/mg (in
those aged 5 years and above), iii) community micro-
filarial load or CMFL (geometric mean number of mf
per skin snip (mf/ss) in those aged 20 years and
above [28]), iv) MFC prevalence, and v) MFAC preva-
lence. Additional file 1 describes the calculation of
the parasitological indices (mf prevalence, AM, WM,
CMFL, MFC and MFAC) (see Text S4. Calculation of
parasitological indices).
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Fig. 2 Temporal trends in therapeutic coverage (%) of ivermectin
treatment for the eligible Yanomami population in the Venezuelan
part of the Amazonian focus. From 1993 through 1999, treatment
was distributed annually by mobile teams. In 2000 treatment
frequency was increased to twice per year and in 2009 to four times
per year. a Coverage of annual and twice per year treatment. b
Coverage of three-monthly treatment since 2009 (black, grey,
hatched and dotted bars indicate, respectively, the therapeutic
coverage in the first, second, third and fourth quarters of the year).
The red horizontal line at 85 % in both (a) and (b) indicates the
minimum coverage of eligibles that needs to be reached and
sustained to interrupt transmission according to OEPA’s strategy
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Entomological evaluations and transmission indices
Baseline and pre-ivermectin MDA
Detailed entomological evaluations were carried out be-
tween 1982 and 2000 in two sentinel communities
(Koyowë (=Coyowë) and Niayopë (=Niyayowë) from the
hyperendemic geographical areas of Orinoquito and Par-
ima, respectively. In these communities, the proportion
of flies with O. volvulus L3 larvae and the mean number
of L3 larvae per fly were evaluated using classical dissec-
tion methods, examining the abdomens, thoraces, and
heads of flies [10]. The baseline transmission indices for
S. guianense s.l. were calculated according to [29].
During ivermectin MDA
In a selection of sentinel (Hasupiwei, Pashopëka,
Koyowë) and extra-sentinel (Arokofita) communities,
and during several consecutive collection days (e.g.,
three to five days or until twelve days in some cases),
host-seeking S. guianense s.l. females were collected
throughout the high O. volvulus transmission seasons
(January–March/February–April or September–Novem-
ber) by using collecting protocols adjusted to the local
transmission conditions previously established in the
area and known periods of highest biting activity by par-
ous flies [11, 30]. All the simuliid females that landed on
two human attractants selected from each community,
working simultaneously but positioned at a distance of
at least 50 m apart, were caught with manual aspirators
by a team of two collectors during the first 50 min of
each hour, beginning at 09:00 h and ending at 17:50 h,
with one break of two hours at midday (12:00–14:00 h),
due to a lull in biting density by parous flies during such
period [30], for a total of 7 h of collection each day. Flies
were collected before procuring a blood meal. Attrac-
tants received ivermectin one week prior to participating
in fly collection in order to minimise the possibility of
the flies becoming infected with ingested mf (if not
caught soon enough after landing on the attractants;
which could give positive results in the PCR analyses de-
scribed below). Whenever possible, the collection teams
in each community were the same throughout the sur-
veys to minimize variations resulting from individual dif-
ferences in catching ability. In the field, all hourly-
caught flies were anesthetized with chloroform vapour,
identified to species, and counted by community, date,
day and hour of the day. The number of collection days
depended on the biting density in each community in
order to reach a number of at least 6000 flies as de-
scribed below.
Polymerase chain reaction (PCR) using O. volvulus-
specific DNA probes has been generally applied to
examine pools of flies in the OEPA region [21]. There-
fore, for each community, flies were combined into
pools containing 200 flies per pool (smaller pools con-
taining remaining flies were also analysed), and the
heads and bodies were tested separately for O. volvulus
using a species-specific PCR assay [31] (conducted by
MAR, TRU). Details of protocols for genomic DNA
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Fig. 3 Ivermectin rounds by geographical sub-area in the Venezuelan part of the Amazonian focus. The number of treatment rounds achieving
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purification and parasite detection have been published
elsewhere [32]. To maximize the efficiency of the screen-
ing process, insect body pools were analyzed first; if any
of those pools were positive, all of the head pools were
then analyzed, providing an estimate of the infectivity
rate (the prevalence of flies carrying only L3 infective
larvae in the head). The Pool Screen® software (Version
2.0; University of Alabama, Birmingham, AL) was used
to estimate the proportion of positive head pools in the
PCR assay and the associated 95 % confidence intervals
(95 % CIs) [33]. This software employs a Bayesian
method to calculate the probability of infection of an in-
dividual blackfly from the number of positive pools and
the size of the pools is used to calculate the infectivity
rate in the community. Since parity status (proportion of
flies that have already laid a batch of eggs) is a very la-
borious parameter to determine routinely in the field,
OEPA’s entomological criterion for cessation of treat-
ment and commencement of surveillance has been sim-
plified to <1 infective fly per 2000 (0.05 %) flies tested
(i.e., assuming that 50 % of flies are parous). To reach
this operational threshold, it has been determined that
the minimum sample size required to have enough
power to detect a statistically significant prevalence of
infective flies lower than 0.05 % (i.e. not included in the
95 % CI), given that no infective fly may be found, is at
least 6000 flies per community [21, 34]. Additional file 1
provides details of the calculation of the transmission in-
dices (hourly biting rate (HBR), seasonal biting rate
(SBR), seasonal transmission potential (STP) and annual
transmission potential (ATP) (see Text S5. Calculation of
transmission indices).
Serological evaluations
Serological evaluations were conducted only during the
ivermectin MDA period with the aim of measuring the
prevalence in samples of children of IgG4 antibodies to
Ov-16—a recombinant O. volvulus antigen able to signal
prepatent infections—[35, 36]. ELISA Ov-16 testing is
currently being used for serosurveys of children in areas
where transmission is deemed to have been interrupted
in the Americas [33, 37, 38]. The serological protocol
was as follows [36]. Sterile procedures were used to
prick the fingers of all participants and four to six drops
of blood (80–120 μL) were absorbed onto Whatman No
2 filter paper. The filter paper blood samples were dried,
separated by sheets of paper, and then bundled and
stored in sealed plastic bags in a cooler until they were
returned to the laboratory where they were stored at
−20 °C. Two 6-mm punches of blood-saturated filter
paper were placed in a phosphate-buffered saline-Tween
0.05 % and bovine serum albumin 5 % buffer and eluted
overnight at 4 °C. The elution was then run in duplicate
in a standard ELISA to detect IgG4 antibodies against
the Ov-16 recombinant antigen. A 5-year cumulative in-
cidence rate of <1 new case per 1000 susceptible chil-
dren (0.1 %) is the level acceptable in the OEPA region
provided that the appropriate population size is available
[21]. Here, and following [34], the prevalence of Ov-16
antibodies is taken as equivalent to this cumulative inci-
dence rate. Consequently, to calculate a prevalence sta-
tistically significantly lower than 0.1 % (i.e. with a 95 %
CI not including this value), and assuming no positives,
a sample size of at least 3000 children <10 years of age
is required. In the Amazonian focus, given the small
community sizes, it is difficult to find this number of
children. Consequently, we aimed to show a prevalence
of Ov-16 < 1 %, requiring a minimum sample size of 300
children. We tested 396 children aged <10 years
throughout the 16 endemic (sentinel and extra-sentinel)
communities included in this study during 2013.
Results
Parasitology and ophthalmology
Baseline and pre-ivermectin MDA
Pre-treatment data (Table 2) showed high prevalence of
microfilarial infection by skin biopsy in sentinel and
extra-sentinel communities, ranging from 56 % in
Pokoshiprare to 100 % in Waharafitha and Toumawei
(in the last two only individuals aged ≥10 years were ex-
amined). In general, the levels of initial endemicity var-
ied from hyperendemic to very highly hyperendemic or
holoendemic, with 11 out of the 16 communities (69 %)
having mf prevalence ≥80 %. The highest values of infec-
tion intensity were recorded in Toumawei (AM= 231.2
mf/mg; WM= 102.6 mf/mg; CMFL = 104.7 mf/ss). Re-
garding ocular onchocerciasis, the prevalence of MFC
was lowest in Awei (18 %) and highest in Waharafitha
(50 %), the latter also being the community with the
highest prevalence of MFAC (75 %).
During ivermectin MDA
The results of the parasitological surveys conducted at
various time points during ivermectin MDA are shown
in Table 3 and, for a selection of communities, graphic-
ally in Fig. 4. To avoid parasitological and entomological
evaluations being conducted too soon after the last treat-
ment round―which would lead to erroneous conclu-
sions about the effectiveness of the programme―the
immediately prior round of treatment was suspended.
Therefore, in those communities receiving 6-monthly
treatment, epidemiological evaluations were conducted
one year after the last treatment round. In those com-
munities receiving 3-monthly treatment, the evaluation
surveys were conducted 6 months after the last treat-
ment round.
The prevalence of O. volvulus mf in most of the com-
munities declined markedly from pre-treatment levels
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(58 to 100 % reduction). According to the results of the
most recent epidemiological evaluation (2008–2009 for
Awei and 2013–2015 for the remainder), 8 out of 16
(Awei, Kanoshewë, Niayopë, Masiriki, Arokofita,
Okiamo, Warapawë, and Pokoshiprare) had 0 mf in
skin (and eyes), and 7 out of the 8 remaining communi-
ties had CMFL <1 mf/ss. A striking decline was also
observed in the prevalence of MFC (Fig. 4a) and MFAC
(Fig. 4b), with the prevalence of MFAC decreasing to
zero in 5 communities.
By contrast, the communities of Hasupiwei, Pasho-
pëka, Koyowë, Kakarama, Waharafitha, Matoa, Yaurawë,
and Toumawei still show mf in skin (and eyes), with
prevalence of MFC as high as 12 % (Fig. 5a, d). Of these
Table 2 Prevalence and intensity of Onchocerca volvulus microfilariae (mf) in the baseline and pre-ivermectin MDA period
(1981– 2000), in sentinel and extra-sentinel communities of the Amazonian focus of southern Venezuela
Geographical sub-area Community
(altitude, masl)
Positive/
examined
Prevalence (%) of skin mf
(95 % CI)
AM†
(mf/mg)
WM§
(mf/mg)
CMFL‡
(mf/ss)
MFC¶
(%)
MFAC¦
(%)
Sentinel communities
Guaharibos 1 Hasupiwei
(200)
39/47b 83.0 (69.2, 92.4) 50.4 12.7 21.3 – –
36/44c 81.8 (67.3, 91.8) 48.7 20.3 43.7 – –
39+,d – – – – 46.2 43.6
Jénita –Putaco 2 Awei
(162)
15/24b 62.5 (40.6, 81.2) 61.3 11.4 52.4 – –
15/18d 83.3 (58.6, 96.4) 60.6 10.8 14.4 17.6 5.9
3 Pashopëka
(240)
29/38b 76.3 (59.8, 88.6) 33.8 9.6 19.7 – –
43/51d 84.3 (71.4, 93.0) 49.9 14.1 17.4 39.2 0
Orinoquito 4 Koyowë
(250)
54/64a 84.4 (73.1, 92.2) 146.3 25.7 72.6 – –
59/72c 81.9 (71.1, 90.0) 80.2 18.8 11.0 – –
54+,d – – – – 35.2 13.0
5 Waharafitha
(260)
36/36e 100 (90.3, 100) 62.1 23.0 57.7 50.0 75.0
6 Matoa
(360)
51/53e 96.2 (87.0, 99.5) 84.4 36.2 50.8 17.0 24.4
Parima B 7 Kanoshewë*
(819)
34/48d 70.8 (55.9, 83.0) 12.5 3.6 4.6 – –
54+,d 5.6 0
8 Niayopë*
(950)
120/179a 67.0 (59.6, 73.9) 44.5 7.6 43.2 – 10.0
22+,d 4.6 0
Extra-sentinel communities
Peñascal 9 Yaurawë
(198)
19/20d 95.0 (75.1, 99.1) 133.3 38.7 68.6 29.3 37.9
Parima A 10 Masiriki
(990)
19/21d 90.5 (69.6, 98.8) 122.8 26.6 31.1 – –
11 Toumawei
(1037)
19/19d 100 (82.4, 100) 231.2 102.6 104.7 – –
Parima B 12 Arokofita*
(871)
22/31d 71.0 (52.0, 85.8) 9.3 2.9 7.6 – –
13 Okiamo*
(927)
13/36d 36.1 8.8 0.98 1.1 – –
8+,d 25.0 0
Parima C 14 Warapawë
(1007)
23/24d 95.8 (78.9, 99.9) 79.7 20.1 15.6 – –
Shamatari 15 Kakarama**
(669)
39/47b 83.0 (69.2, 92.4) 50.4 12.7 33.8 – –
16 Pokoshiprare**
(721)
19/33b 57.6 (39.2, 74.5) 39.6 4.7 30.0 – –
†AM arithmetic mean no. of mf/mg; §WM geometric mean (of Williams) no. of mf/mg; ‡CMFL community microfilarial load, the geometric mean no. of mf per skin
snip (ss) in those individuals aged ≥20 years; ¶MFC prevalence of mf in cornea; ¦MFAC prevalence of mf in the anterior chamber of the eye; a1981, b1995, c1997,
d1998, e2000; +examined for ocular lesions only, *the community of Niayopë, formerly called Niyayowë and studied in 1981, included Kanoshewë, Arokofita and
Okiamo; therefore, although these communities did not exist as separate entities at the time of the baseline study in 1981, their infection levels are assumed to
be the same as those of Niyayowë/Niayopë; ** Kakarama and Pokoshiprare originated from Yoreshiana A and B, studied by [26]
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communities, the latter four had an initial prevalence of
microfilaridermia ≥95 %.
Entomological evaluations
Baseline and pre-ivermectin MDA
Table 4 presents data on biting and infectivity rates of S.
guianense s.l. in two sentinel communities prior to ivermec-
tin MDA. Biting rates were high, particularly in Koyowë,
where the monthly biting rate (MBR) reached values up to
23,997 bites person−1 month−1 and the monthly transmis-
sion potential (MTP) up to 576 L3 person−1 month−1. Sea-
sonal biting rates (during the higher transmission months of
January through March/April plus October through
November) were in excess of 100,000 bites per person per
transmission season. As these flies were processed by man-
ual dissection, it was possible to determine both the propor-
tion of infective flies and the number of L3 in the flies, with
the latter ranging from 0.001 to 0.036 L3/fly (Table 4). In
Niayopë (=Niyayowë) the biting rates and transmission indi-
ces were lower, with an average MBR of 727 bites person−1
month−1, a seasonal biting rate of roughly 3000 flies per per-
son per transmission season, and a maximum MTP of
15 L3 person−1 month−1. Additional file 1 illustrates the
dynamics of biting rates and transmission potentials
throughout the year for the baseline entomological studies
conducted in Koyowë and Niyayowë (see Figures S1–S3),
Table 3 Prevalence and intensity of Onchocerca volvulus microfilariae during ivermectin MDA (2001–2015), in sentinel and extra-
sentinel communities of the Amazonian focus of southern Venezuela
Community Positive/
examined
Prevalence (%) of
skin mf (95 % CI)
AM†
(mf/mg)
WM§
(mf/mg)
CMFL‡
(mf/ss)
MFC¶
(%)
MFAC¦
(%)
Sentinel communities
1 Hasupiwei 5/43b 11.6 (3.9, 25.1) 0.26 0.13 0.11 11.8 0
4/55c 7.3 (2.0, 17.6) 0.13 0.07 0.03 10.0 2.0
2 Awei 11/23a 47.8 (26.8, 69.4) 2.06 0.94 3.04 – –
0/13b 0 (0, 24.7) 0 0 0 0 0
3 Pashopëka 20/28a 71.4 (51.3, 86.8) 1.74 0.88 1.04 – –
10/32b 31.2 (16.1, 50.0) 2.51 0.17 1.60 11.1 7.4
1/49c 2.0 (0.10, 10.9) 0.03 0.02 0.03 4.5 0
4 Koyowë 60/77a 77.9 (67.0, 86.6) 16.4 4.7 20.2 36.0 13.0
24/58b 41.4 (28.6, 55.1) 3.4 1.1 1.9 20.4 6.1
7/98c 7.1 (2.9, 14.2) 0.18 0.09 0.17 11.9 0
5 Waharafitha 39/80b 48.8 (37.4, 60.2) 3.33 0.91 1.19 7.5 12.5
5/40c 12.5 (4.2, 26.8) 0.22 0.12 0.17 0 0
6 Matoa 14/35b 40.0 (23.9, 57.9) 3.66 0.91 1.03 8.3 0
7 Kanoshewë 1/11b 9.1 (0.2, 41.3) 0.06 0.05 0 – –
0/25c 0 (0, 13.7) 0 0 0 – –
8 Niayopë* 4/12b 33.3 (9.9, 65.1) 0.49 0.17 0 – –
0/38c 0 (0, 9.3) 0 0 0
Extra-sentinel communities
9 Yaurawë 11/37b 29.7 (15.9, 47.0) 0.99 0.43 0.55 20.0 16.0
16/77c 20.8 (12.4, 31.5) 1.75 0.40 0.7 11.1 3.7
10 Masiriki 0/21c 0 (0, 16.1) 0 0 0c – –
11 Toumawei 2/25c 8.0 (1.0, 26.0) 0.10 0.05 0.10 – –
12 Arokofita 0/21c 0 (0, 16.1) 0 0 0 – –
13 Okiamo 0/38c 0 (0, 9.3) 0 0 0 – –
14 Warapawë 3/30b 10.0 (2.1, 26.5) 0.04 0.04 – – –
0/31c 0 (0, 11.2) 0 0 0
15 Kakarama** 1/41c 2.4 (0.1, 12.9) 0.03 0.02 0.05 – –
16 Pokoshiprare** 0/60c 0 (0, 6.0) 0 0 0 – –
†AM arithmetic mean no. of mf/mg, §WM geometric mean (of Williams) no. of mf/mg; ‡CMFL community microfilarial load, the geometric mean no. of mf per skin
snip (ss) in those individuals aged ≥20 years; ¶MFC prevalence of mf in cornea; ¦MFAC prevalence of mf in the anterior chamber of the eye; a2001, b2008–2009,
c2013– 2015; *formerly called Niyayowë; **Kakarama and Pokoshiprare originated from Yoreshiana A and B, studied by [26]
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as well as the relationship between the proportion of
infective flies and the mean number of L3 larvae per fly
(Additional file 1: Figure S4). Additional file 1: Table S2
provides a comparison of manual dissection and PCR for
a S. guianense s.l. population sample obtained during May
2000. The corresponding infectivity rates, 0.26 % (95 % CI
0.10–0.53 %) by dissection and 0.38 % (95 % CI 0.19–
0.69 %) by PCR are in agreement with the value of 0.37 %
for the entire baseline study period (Table 4).
During ivermectin MDA
Results of the entomological evaluations carried out
from 2006 to 2013 in Hasupiwei, Pashopëka, Koyowë
and Arokofita are presented in Table 5. The seasonal bit-
ing rates in Koyowë were consistent with those recorded
during 1982–2000 (Table 4), suggesting that any decline
in transmission is not due to secular environmental and
ecological changes affecting vector abundance but likely
due to the treatment programme. In 2006, after 12
rounds of ivermectin treatment with ≥85 % of coverage,
7 out of 203 pools of S. guianense s.l. heads from
Koyowë were PCR positive, leading to a prevalence of
infective flies of 1.4 per 2000 tested flies (0.07 %), in con-
trast with the 7.4 (0.37 %) infective flies per 2000 dis-
sected flies recorded at baseline (Table 4). This
represents an 81 % reduction in infectivity. The esti-
mated seasonal transmission potential was 39 L3 (head)
per person per transmission season in contrast with
1406 L3 (all) at baseline (a 97 % reduction). Four years
later, in 2010, and after 22 rounds if ivermectin MDA (7
annually from 1993 to 1999; 11 biannually from 2000 to
2008, and 4 quarterly during 2009), all 223 body pools
representing 10,882 flies of S. guianense s.l. tested were
PCR negative. This was also the case in 2012–2013,
when 13,117 S. guianense s.l. flies were tested. However,
the upper 95 % CI for the STP in 2010 was 25 and for
2012–2013 it was 19 L3 larvae/person/transmission sea-
son (accounting fot uncertainty in the estimates). In
Hasupiwei, Pashopëka and Arokofita, after 2–3 years of
quarterly ivermectin treatment, all 8085, 6464 and
12,793 flies respectively tested in 2012–2013 were PCR
negative (with the upper 95 % CI for STP of 3–4 L3/per-
son/transmission season).
Serological evaluation
Table 6 summarises by geographical sub-area the results
of the Ov-16 seroprevalence surveys conducted in 2013.
Overall, 26 children aged 1–10 years (from 6 communi-
ties) were seropositive out of a total of 396 examined
(6.6 %; 95 % CI 4.3–9.5 %). Most of the seropositive chil-
dren (22/26, 85 %) clustered in 5 communities of the
Orinoquito sub-area. However, the prevalence for chil-
dren aged 1–5 years was of 1.8 % (4/218), with only 3
communities (Koyowë, Matoa and Yaurawë) showing
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specific antibodies to O. volvulus Ov-16 for this age
group (Table 6).
Discussion
In this paper we present a compendium of the parasito-
logical, ophthalmological, entomological and serological
data obtained in hyperendemic communities of the
Venezuelan part of the Amazonian onchocerciasis focus
since the original studies conducted in the Parima and
Orinoquito areas in 1981 [8]. These studies, and those
presented previosuly [7, 22, 25, 26] provided the epi-
demiological baseline situation prior to the introduction
of ivermectin MDA. Both the geographical and thera-
peutic coverage of annual administration were low when
the programme first started in a few communities in
1993 (Koyowë, Kanoshewë, Niayopë). In 2000 a twice
per year treatment strategy was adopted, and in 2009,
treatment frequency was increased to four times per year
(Fig. 2).
Overall, skin microfilarial prevalence and intensity
have declined substantially, with reductions in preva-
lence ranging from 58 % (Matoa) in 2009 to 100 %
(Awei, Niayopë, Masiriki, Arokofita, Okiamo, Warapawë
and Pokoshiprare) in 2015. By 2015, CMFL and MFAC
have become, respectively, negative in 7/16 (44 %) and
5/7 (71 %) of the communities examined for these indi-
cators. Communities of the Orinoquito sub-area
(Koyowë, Waharafitha and Matoa) are still positive for
O. volvulus mf in skin and eyes, likely due to their
holoendemic status at baseline and the very high vector
biting rates characteristic of the Orinoquito ranforest
bioclime (~245,000 bites person−1 year−1 and 104,000
bites per transmission season in Koyowë, Table 4). This
is despite these communities having received 35 rounds
of ivermectin with a coverage ≥85 % of eligibles (~75 %
of the total population) by 2015 (Fig. 2c). By contrast,
communities located in the Parima sub-areas (Niayopë,
Masiriki, Toumawei, Arokofita, Okiamo, Warapawë,
Kakarama and Pokoshiprare) have experienced greater
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Fig. 5 Temporal trends of ocular onchocerciasis prevalence in sentinel
communities of the Venezuelan part of the Amazonian focus. a
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Table 4 Biting rate, infectivity rate, mean number of O. volvulus L3 per fly, and transmission potentials of S. guianense s.l. in the
baseline and pre-ivermectin MDA period (1981–2000) in two sentinel communities of the Amazonian focus of southern Venezuela
Community
(years)
L3-positive/
dissected
MBRa
(95 % CI)
SBRb
(95 % CI)
Infectivity rate
(%) (95 % CI)
No. L3/fly
(range)
MTPc
(range)
STPd ATPe
Koyowë
(1982–2000)
108/29,490 20,420
(16,843–23,997)
103,516
(81,142–125,889)
0.37
(0.30–0.44)
0.0079
(0.001–0.036)
179
(14–576)
1406 2020
Niayopëf
(1982–1993)
31/4742 727
(417–1036)
2920
(2538–3301)
0.65
(0.44–0.93)
0.0143
(0.001–0.036)
6
(0–15)
40 72
aMBR: Monthly biting rate = arithmetic mean number of bites per person per month
bSBR: Seasonal biting rate = the number of bites per person per transmission season (January–March plus October–November)
cMTP: Monthly transmission potential = number of L3 per person per month =MBR ×mean number of L3 per fly (located anywhere in the fly’s body)
dSTP: Seasonal transmission potential = the sum of MBR for the months with higher transmission (January–March plus October–November) with L3 larvae located
anywhere in the fly’s body
eATP: Annual transmission potential = number of L3 per person per year = the sum of MBR values throughout the year with L3 larvae located anywhere in the
fly’s body
fThe community of Niayopë was formerly called Niyayowë
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reductions in mf prevalence (ranging from 92 to 100 %),
probably due to the lower vector density of S. guianense
s.l. in this highland savannah bioclime (8700 bites per-
son−1 year−1 and 2920 bites per transmission season as
recorded in Niayopë, Table 4).
In the OEPA region, absence or near absence of L3 lar-
vae in the head of blackfly vectors (as measured by pool-
screen PCR in samples of 6000–10,000 flies), a 99 % re-
duction in the intensity of transmission (as measured by
seasonal transmission potentials), and the absence of de-
tectable O. volvulus infection (by parasitological or im-
munological diagnostics) in children have been the WHO
criteria followed to certify focal interruption of parasite
transmission [21]. Prior to reaching this epidemiological
status, the focus starts to show declining to very low or
negative parasitological results in skin, eyes (indicators of
reversible morbidity) and flies, suggesting that transmis-
sion of the infection has been suppressed by the treatment
[21, 34]. Here, we report 81 % reductions in fly infectivity
and 97 % reductions in seasonal transmission potentials,
with an overall prevalence of 7 % in Ov-16 seroprevalence
among children aged up to 10 years and of 2 % among
those under 5 years, providing evidence of suppression of
O. volvulus transmission by the most competent vector of
the focus, S. guianense s.l., in areas formerly hyperendemic
to holoendemic. The dramatic decline in the seropreva-
lence among children and the lack of evidence of parasite-
vector contact suggest that four times per year treatment
has successfully suppressed transmission in many of the
endemic communities. It will now be necessary to main-
tain pressure on the parasite population, continuing to
suppress transmission, until the existing adult female par-
asites are either killed or rendered sterile by repeated iver-
mectin treatments [20].
Ivermectin is expected to have a faster impact in
those areas of the Amazonian focus with lower vector
competence blackfly species (e.g. S. oyapockense s.l. and/or
S. incrustatum [12, 39], which sustain hypo- to
Table 5 Biting rate, infectivity rate, and onchocerciasis transmission potentials of S. guianense s.l. during ivermectin MDA
(2006–2013) in sentinel and extra-sentinel communities of the Amazonian focus of southern Venezuela
Community
(Year)
Flies collected
and analysed
SBRa
(95 % CI)
Infectivity rate (%)b
(95 % CI)
STPc
(95 % CI)
Hasupiwei
(2012–2013)
8085 15,806
(13,237–18,858)
0
(0–0.025)
0
(0–3.7)
Pashopëka
(2012–2013)
6464 13,048
(11,323–15,026)
0
(0–0.03)
0
(0–3.9)
Koyowë
(2006)
10,194 56,051
(47,529–66,093)
0.07
(0.025–0.13)
39.2
(15.1–72.1)
Koyowë
(2010)
10,882 72,237
(60,839–85,754)
0
(0–0.035)
0
(0–25.3)
Koyowë
(2012–2013)
13,117 130,143
(115,704–146,736)
0
(0–0.015)
0
(0–18.9)
Arokofita
(2012–2013)
12,793 40,857
(35,308–47,238)
0
(0–0.01)
0
(0–3.1)
aSBR: Seasonal biting rate = Geometric mean number of bites per person per transmission season
bCalculated as the number of positive fly heads for O. volvulus L3 DNA per 2000 flies examined and expressed as a percent
cSTP: Seasonal transmission potential = the number of L3 (head only) per person per transmission season = SBR × infectivity rate (expressed as a proportion)
assuming that an infective fly carries on average one infective larva in the cephalic capsule
Table 6 Prevalence of IgG4 antibodies to Ov-16 in children aged 1–10 years tested in 2013, by geographical sub-area in the
Amazonian focus of southern Venezuela
Geographic sub-areaa 1–5 years
(positive/examined)
Seroprevalence
(%) (95 % CI)
6–10 year
(positive/examined)
Seroprevalence
(%) (95 % CI)
Total
(positive/examined)
Seroprevalence
(%) (95 % CI)
6 Jénita–Putaco 0/15 0 (0–21.8) 0/14 0 (0–23.2) 0/29 0 (0–11.9)
15 Guaharibos 0/13 0 (0–24.7) 0/8 0 (0–36.9) 0/21 0 (0–16.1)
16 Peñascal 1/23 4.3 (0.1–21.9) 2/15 13.3 (3.7–37.9) 3/38 7.9 (1.7–21.4)
18 Orinoquito 3/62 4.8 (1.7–13.3) 19/54 35.2 (23.8–48.5) 22/116 19.0 (12.9–27.0)
19 Parima B 0/41 0 (0–8.6) 0/32 0 (0–10.9) 0/73 0 (0–4.9)
20 Parima C 0/18 0 (0–18.5) 0/10 0 (0–30.9) 0/28 0 (0–12.3)
21 Parima A 0/9 0 (0–33.6) 0/15 0 (0–21.8) 0/24 0 (0–14.3)
24 Shamatari 0/37 0 (0–9.5) 1/30 3.3 (0.08–17.2) 1/67 1.5 (0.04–8.0)
Total 4/218 1.8 (0.5–4.6) 22/178 12.4 (8.3–18.0) 26/396 6.6 (4.3– 9.5)
aNumbering of sub-areas as in Table 1 and Fig. 1
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mesoendemic transmission [22], or where vector biting
rates are lower and perhaps closest to critical biting rates
necessary to maintain endemic transmission (basic
reproduction ratio, R0 ≥ 1 [40]). These threshold biting
rates do not only depend on vector competence for O. vol-
vulus, but also on the human blood index (HBI, the pro-
portion of vector blood meals of human origin) of the
various blackfly species and populations therein. At
present, this parameter is unknown for the simuliid spe-
cies prevailing in the Amazonian focus, but field and the-
oretical studies on S. damnosum s.l. in West Africa
indicate that the HBI can be highly variable [41] and pos-
sibly host and fly density dependent [42]. Given that the
Venezuelan part of the Amazonian focus is sparsely inhab-
ited by human populations, it is likely that the HBI is rela-
tively low and threshold biting rates correspondingly high.
Serological data (albeit with low sample sizes reflected in
the 95 % CI shown in Table 6) suggest that suppression of
transmission may have been more rapidly accomplished in
those communities with seasonal biting rates (SBRs) of
S. guianense s.l. lower than 50,000 bites/person/trans-
mission season after at least 4 rounds of treatment
with coverage ≥85 % of eligible population. In these
communities 133 children under 5 years of age from
Pashopëka (Jénita–Putaco); Hasupiwei (Guaharibos);
Arokofita, Kanoshewë, Niayopë and Okiamo (Parima B);
Warapawë (Parima C); Masiriki and Toumawei (Parima
A), and Kakarama (Shamatari) were negative for Ov-16
(Table 6). This contrasts with the situation in communi-
ties with higher SBR values (Koyowë and neighbouring vil-
lages in Orinoquito and Peñascal, with SBR >50,000 bites/
person/ transmission season), where 4/85 (5 %) children
aged 1–5 years were seropositive in 2013.
Modelling studies conducted with the EPIONCHO
transmission model in African savannah settings [43] have
suggested that switching to a twice per year treatment
strategy during an ongoing annual treatment programme
can substantially decrease (nearly by half in highly hyper-
endemic settings) the additional number of years required
to reach the provisional, operational mf prevalence thresh-
olds suggested by the African Programme for Onchocer-
ciasis Control [44] to achieve focal elimination of
onchocerciasis. In hyperendemic settings this switch can
lead to cost savings. However, these provisional thresholds
are not equivalent to transmission breakpoints. A recent
comparison of the (stochastic) ONCHOSIM and (deter-
ministic) EPIONCHO models highlights this difference,
and indicates that more than 20 years of twice per year
treatment (40 treatment rounds) would be required to
drive the parasite population to elimination when the ini-
tial microfilarial prevalence is greater than 90 % and the
coverage of treatment is between 65 and 80 % of the total
population (80 to 95 % of eligible individuals) [45]. These
projections appear compatible with the results seen in the
Amazonian focus in those holoendemic communities in
which vector biting rates are very high such as Koyowë.
Quarterly treatments may help to accelerate progress to
elimination in these communities by further reducing the
amount of transmission that takes place between consecu-
tive ivermectin rounds, increasing effective coverage, and
exerting a macrofilaricidal effect [19, 20]. Interestingly, the
presence of live fertile worms in the host population, as
well as of infected (mf positive) people is predicted for
2015 in Koyowë by simulations conducted (by DR) with
the EUSIMON model (see [46] for a published precursor),
a community with the highest number of treatment
rounds (37). This model also predicts the occurrence of
transmission and of seropositivity in children by 2015.
However, the EUSIMON simulations conclude that the
chance of recrudescence in this locality is low if ivermec-
tin treatment were to be interrupted, provided there is no
migration of infected people and/or flies into the assumed
closed population.
More likely, in the Amazonian focus, and due to the
Yanomami network of kinship ties, alliances and hostilities
[6, 22], onchocerciasis occurs in a network of intercon-
nected nodes reminiscent of a metapopulation structure,
the degree of connection depending both on vector and
human movement―the latter being possibly more im-
portant and/or better documented. This spatial structure
has important repercussions for onchocerciasis transmis-
sion and control, as some sub-areas/communities that by
themselves may not be able to sustain endemic transmis-
sion, may receive an important and periodic influx of
heavily infected people from highly endemic areas, making
it possible for the infection to persist or be re-introduced.
This potential exchange of parasites between otherwise
different transmission zones by virtue of the Yanomami
micro- and macro-movements [47], may also weaken po-
tential barriers to gene flow. This may allow spread of on-
chocerciasis from currently non-controlled or less well
controlled areas, calling for the development of spatially-
explicit, patch transmission models and anthropology-
based research avenues for onchocerciasis control in the
Amazonian focus. The transport of Onchocerca parasites
along the reticular nature of the Yanomami use of space
may indeed be very diffuse, necessitating intensive treat-
ment in all sub-areas; however, if particular networks
could be identified as being responsible for most transmis-
sion, a more targeted approach could be beneficial to-
wards the goal of achieving elimination.
Remaining challenges and directions for future work
The semi-nomadic characteristics of the human popula-
tion, the remoteness of the Yanomami territory, the
holoendemic status of some areas, and the ongoing iden-
tification of new endemic communities in the Venezue-
lan part of the Amazonian focus constitute the main
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challenges for the elimination of onchocerciasis in the
Amazonian focus. From 2009, ivermectin treatment fre-
quency has been increased to four times per year in
80 % of the hyperendemic communities in an attempt to
hasten interruption of transmission in areas showing
slow progress or in communities recently identified and
incorporated into the programme at later stages. Sus-
taining a high geographical and therapeutic coverage for
each treatment round is essential. Only the first round
of the 2012–2014 quarterly distributions reached the
≥85 % goal. Besides, since the sentinel and extra-sentinel
communities included in this study were partly selected
because of relative facility of access, there is the possibil-
ity that more remote communities received a lower
treatment coverage and/or frequency. Currently, there is
a total of 72 communities identified as being remote
(~30 % of the total), with a population of 3359 individ-
uals (~47–50 individuals per shapono). This represents
approximately 25 % of the total population. Most of
these communities are receiving regular treatment, and
many of them have received more than 8–12 treatment
rounds (Pasumopë, Chalbaud, Mayo and Hashimu sub-
areas). However, there are communities located in the
Upper Siapa and Upper Ocamo-Parima sub-areas that
are only accessible by helicopter (25–30 communities,
with ~1000–1500 individuals). This represents only 11 %
of the total population and 12 % of all the communities
under treatment. Treatment is delivered to these com-
munities when helicopter support is available. Depend-
ing on their endemicity status and their connectedness
with well-controlled areas, these less accessible commu-
nities could pose a risk of infection re-introduction. The
use of high spatial-resolution satellite data to identify re-
mote communities in the rainforest is a strategy cur-
rently used in an attempt to delineate the extent of the
focus, the distribution of transmission zones [6], and the
intensification of treatment efforts that will be required
to achieve elimination over the entire focus. The pro-
spect of deploying test-and-treat doxycycline treatment
as a complementary macrofilaricidal therapy in commu-
nities with suppressed transmission has also been con-
sidered [48]. Finally, in May 2014, under the auspices of
the WHO, Brazil and Venezuela signed a bi-lateral
memorandum of understanding calling for a closely co-
ordinated effort between both national programmes in
order to reach the goal of onchocerciasis elimination
from the Yanomami area. A first joint meeting was held
in February 2015, and an action plan for 2015–2016 was
agreed and is being implemented [49].
Conclusions
Our results contribute to the ongoing success of the
OEPA strategy [4, 5, 14, 33, 37, 38]. This success has
spurred prospects of onchocerciasis elimination in
Africa, particularly by increasing coverage and adopting
a twice per year treatment strategy [50–54]. However,
the OEPA experience may not be fully reproducible in
African foci. In the OEPA region treatment has been de-
livered by mobile teams, who observe directly that iver-
mectin tablets are ingested by the individuals receiving
treatment, circumventing the barriers to elimination
posed by the occurrence of systematic non-compliers
that affect African countries, particularly those with
onchocerciasis-loiasis endemic areas [55]. Currently, no
new cases of onchocerciasis-associated blindness have
been reported in most of the OEPA region and ocular
morbidity has been eliminated from eleven of the 13
previously endemic Latin American foci. Parasite trans-
mission has been interrupted in these eleven foci (~96 %
of the total population at risk, representing four of the
six countries where the disease was formerly endemic),
and elimination has been reached in 10 foci (represent-
ing ~78 % of the population at risk). In 2013, onchocer-
ciasis transmission was declared eliminated in Colombia
[56], and by 2014 Ecuador became the second Latin
American country to attain this goal [4, 33]. In Mexico
this target has been reached by 2015 [49, 57] and
Guatemala [58] has filed its verification dossier in the
WHO. The two countries lagging behind, Venezuela and
Brazil, share the most difficult to approach and hard-to-
reach populations of the Amazonian focus, yet our re-
sults show that given sufficient commitment and deter-
mination by the control programme, and unwavering
support by OEPA, it is possible to attain and sustain
high levels of treatment coverage and increased fre-
quency, attesting to the feasibility of suppressing and ul-
timately interrupting transmission in the last bastions of
onchocerciasis in Latin America.
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